- Price
- $487.61
- Day
- -0.54%
- Mkt Cap
- $20.70B
- 52W Range
- $388.73 – $609.35
- Volume
- 327.0K
- Beta
- 0.56
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening.
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the supplemental New Drug Application (sNDA) for nebulized Tyvaso® (treprostinil) Inhalation Solution to treat IPF. United Therapeutics anticipates the agency's review to be complete in late April 2027. Nebulized Tyvaso has not been approved by the FDA for IPF and remains investigational for this indication. “.
Canada Pension Plan Investment Board Acquires New Position in United Therapeutics Corporation $UTHR
Canada Pension Plan Investment Board bought a new position in United Therapeutics Corporation (NASDAQ: UTHR) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 6,200 shares of the biotechnology company's stock, valued at approximately $3,359,000. A number of other institutional investors and hedge
Corient Private Wealth LP Purchases New Holdings in United Therapeutics Corporation $UTHR
Corient Private Wealth LP purchased a new stake in United Therapeutics Corporation (NASDAQ: UTHR) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 15,582 shares of the biotechnology company's stock, valued at approximately $8,443,000. Other institutional investors and hedge funds also recently